MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose C...(programs for the inhaler include; a mult...),Health

Date:8/19/2007

programs for the inhaler include; a multi-product development and licensing agreement with Novartis for its proprietary respiratory compounds, and an inhaler for the systemic delivery of a nerve agent antidote for the US Department of Defense in co-development with the University of Pittsburgh. In addition, MicroDose has undisclosed collaborations ongoing with major pharmaceutical partners in the respiratory market segment.

MicroDose's second drug delivery platform, PolyCap(TM), is a fixed-dose-combination oral dosage technology, which allows two or more drugs to be combined in a single capsule, but separated by a physical barrier. Internal development programs utlilizing PolyCap(TM) are underway in the areas of diabetes, hypertension and hyperlipidaemia. PolyCap(TM) is also available for license to pharmaceutical partners for their combination product needs.

For further information please visit MicroDose's website at http://www.microdose-tech.com

About Diabetes

Diabetes is a chronic health condition where the body is unable to produce or adequately use insulin. Diabetes is broadly grouped into two types -- Type I and Type 2. Type 2 diabetics make up approximately 90% of all diabetics and the incidence of Type 2 diabetes is growing rapidly. According to the World Health Organization, diabetes is reaching epidemic proportions. Approximately 194 million people worldwide suffer from the disease, and it is estimated that the number of people with diabetes will more than double by 2030. Predictions are that one in three children in the U.S. born five years ago will develop diabetes. Direct healthcare costs may be as much as $286 billion worldwide. It is widely accepted that early intervention for Type 2 diabetics by treatment with insulin improves outcomes. However, as Type 2 diabetics are reluctant to inject insulin the introduction of non-invasive insulin delivery formats, such as inhalab
'/>"/>

SOURCE MicroDose Technologies, Inc. Copyright©2007 PR Newswire.

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference